Dexedrine
EmergingPure d-amphetamine — same active drug as Vyvanse but without prodrug protection, slightly cleaner peripheral profile than Adderall (no… | Pharmaceutical · Oral
Aliases (7)
▸Brand options5 known
StatusSchedule II (US DEA) | Schedule 8 (Australia) | Class B (UK) | Class III (Canada CDSA)
▸ Overview TL;DR
Pure d-amphetamine — same active drug as Vyvanse but without prodrug protection, slightly cleaner peripheral profile than Adderall (no L-isomer cardiovascular load). For 20yo Dylan with no diagnosis: SKIP-FOR-NOW. Same brain-dev / age reasoning that rules out other amphetamines applies here. STRONG-CANDIDATE only if a clinical narcolepsy or ADHD diagnosis is established and a prescriber recommends a classical stim.
▸ Mechanism of action
Dextroamphetamine is the (S)-(+)-enantiomer of amphetamine — the more potent CNS-active half. Pure d-amphetamine, no levoamphetamine. This is what makes Dexedrine pharmacologically distinct from Adderall (3:1 mixed d:l salts) and downstream-identical to Vyvanse (which is a lysine-bonded prodrug that the body cleaves into d-amphetamine).
Triple action — how amphetamines actually move dopamine:
- TAAR1 agonism (intracellular). Amphetamine enters monoamine neurons via DAT/NET. Inside, it activates trace amine-associated receptor 1 (TAAR1), which triggers PKA/PKC phosphorylation of DAT → DAT internalizes off the membrane AND reverses its transport direction. Dextroamphetamine is a 3-4× more potent TAAR1 agonist than levoamphetamine, which is the molecular reason d-amphetamine produces more CNS stimulation per mg.
- VMAT2 inhibition + cytoplasmic flooding. Amphetamine displaces dopamine, NE, and serotonin from synaptic vesicles into the cytoplasm. Cytoplasmic monoamine concentrations spike.
- Reverse transport (efflux). With DAT/NET now running in reverse, the cytoplasmic monoamine pool floods out into the synapse — the opposite of how transporters normally work. This is "forced release," distinct from reuptake inhibition (cocaine, methylphenidate) or eugeroic mechanisms (modafinil).
Mild MAO inhibition at high doses adds further amplification.
Why "cleaner than Adderall" is mechanistically real, not just marketing:
- Levoamphetamine (the 25% in Adderall that's NOT in Dexedrine) is the weaker CNS agent but the stronger peripheral sympathomimetic. L-amphetamine has slightly higher cardiovascular and smooth-muscle effects per mg.
- Strip out the L-isomer → fewer peripheral effects (jitters, jaw tension, vasoconstriction, BP spike) per unit of central dopamine release. This is the mechanism behind anecdotal reports that Dexedrine "feels cleaner" or "less anxious" than Adderall.
- The effect is real but modest — both drugs still hit cardiovascular system meaningfully, both still carry the FDA black-box for sudden cardiac death.
vs Vyvanse: Same active drug post-metabolism, different release kinetics. Vyvanse must be cleaved by GI peptidases (lysine bond) before any d-amphetamine appears in plasma → slow ramp, no IV/snort potential, lower abuse liability. Dexedrine IR delivers d-amphetamine directly → fast onset, higher peak, more euphoric, more abusable.
▸ Pharmacokinetics Approximate
Approximate decay curve drawn from the half-life mention(s) in the source notes. Real PK data not yet ingested per compound.
▸Quality indicators4 checks
▸ What to expect Generic
- 1Day 1PK-driven acute peak per administration. Verify dose tolerated.
- 2Week 1Steady-state reached for most daily-dosed pharma.
- 3Week 2-4Therapeutic effect established; titration window if needed.
- 4Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
▸ Side effects + safety Tabbed view
Common (>10% users)
- Appetite suppression (often significant — bigger issue for Dylan's MMA training calorie needs)
- Insomnia / delayed sleep onset (incompatible with Dylan's late-chronotype migration plan)
- Dry mouth
- Increased BP and HR (smaller than Adderall on average, but real)
- Headache
- Weight loss
- Anxiety / nervousness
- Mood elevation that may feel artificial
Less common (1-10%)
- Bruxism (jaw clenching) — less than Adderall but present
- Tachycardia / palpitations
- Vasoconstriction (cold extremities, Raynaud-like)
- Tics / motor stereotypies (especially in adolescents)
- Erectile dysfunction at higher doses
- Mood lability / irritability on taper
Rare-serious (<1% but worth knowing)
- Sudden cardiac death — FDA black-box. Risk concentrated in patients with structural heart disease, family history of sudden cardiac death, or pre-existing arrhythmia. Baseline-healthy young adults at low absolute risk but non-zero.
- Stroke / MI — same population, same risk profile.
- Stimulant psychosis — paranoid/psychotic symptoms at high doses or in vulnerable individuals.
- Cardiomyopathy — chronic high-dose use, isolated case reports.
- Serotonin syndrome when combined with serotonergic drugs (SSRIs, MAOIs, MDMA).
- Dependence + withdrawal — physical and psychological. Withdrawal: anhedonia, hypersomnia, depressed mood, hyperphagia, vivid dreams. Therapeutic-dose discontinuation in compliant patients usually mild; abuse-pattern discontinuation can be brutal.
Specific watch periods
- First 4 weeks: monitor BP, HR, anxiety, sleep
- Months 2-6: tolerance assessment + dose creep watch
- Annual: ECG if any cardiac flag; cardiovascular risk reassessment
▸Interactions8 compounds
- L-tyrosineSynergisticsubstrate replenishment for sustained dopamine synthesis; theoretical basis for blunting late-day crash. Modest evidence.
- MagnesiumSynergisticcounters NMDA-glutamate excitotoxicity, may reduce bruxism and anxiety.
- L-theanineSynergisticanxiolytic counter to peripheral stim load.
- MAOIs (selegiline, phenelzine, tranylcypromine, moclobemide)Avoidhypertensive crisis risk. Even low-dose (1-2.5 mg) selegiline carries this concern. Hard contraindication.
- SSRIs / SNRIsAvoidserotonin syndrome risk plus CYP2D6 inhibition (fluoxetine, paroxetine especially) elevates d-amphetamine plasma levels.
- BupropionAvoidadditive dopaminergic + seizure threshold lowering + CYP2D6 inhibition.
- Other stimulantsAvoid(Adderall, Vyvanse, methylphenidate, modafinil at high dose) — additive cardiovascular load + dopamine downregulation.
- AlcoholAvoidmasks intoxication, cardiovascular load.
▸References13 sources
Dextroamphetamine — Wikipedia
pharmacology overview, enantiomer differences, pharmacokinetics
Amphetamine — StatPearls / NCBI Bookshelf
clinical mechanism, indications, side effects
Dextroamphetamine-Amphetamine — StatPearls / NCBI
clinical comparison data
Dexedrine Spansule prescribing information (FDA)
FDA label, pharmacokinetics, narcolepsy/ADHD indications
DrugBank: Dextroamphetamine
mechanism of action, drug interactions, CYP metabolism
Reynolds et al. 2015, Neuropsychopharmacology — Amphetamine in adolescence disrupts PFC dopamine connectivity (DCC-dependent)
2015primary brain-dev mechanism paper
Amphetamine disrupts dopamine axon growth in adolescence (Nature Communications 2023)
2023male-specific Netrin-1/DCC mechanism
Hammerslag & Gulley 2020 review (PMC7554214)
2020adolescent amphetamine + PFC development synthesis
Groff et al. 2025, J Atten Disord — Risk Factors for Adverse Cardiac Events with Stimulants Across the Lifespan
2025current cardiovascular risk data
FDA Updating Warnings to Improve Safe Use of Prescription Stimulants
current FDA stimulant safety position
Medfinder: Dexedrine Shortage Update 2026
2026current shortage / quota / pricing data
SingleCare: Dexedrine vs Adderall
clinical comparison, peripheral effect profile
PsychCentral: Dexedrine vs Vyvanse
kinetic and subjective comparison